Investors
Building the material platform for clinical biofabrication.
LifeGlue Technologies is developing a patent-protected, animal-free hydrogel platform designed to support engineered human tissues from research through clinical translation and scalable manufacturing.
Why now
Biofabrication is advancing. The materials need to catch up.
Tissue engineering, regenerative medicine, advanced cell therapies and biofabrication are progressing rapidly. Biomaterials remain a critical bottleneck for reproducibility, scale-up and clinical translation — driving growing demand for animal-free, chemically defined and clinically translatable materials.
Current challenges
Animal-derived inputs
Introduces biological variability and additional translational complexity.
Batch variability
Makes reproducibility, scale-up and site transfer more difficult.
Complex crosslinking workflows
Additional UV, photoinitiators or crosslinking steps increase process complexity.
Material changes during development
Switching materials between research and later-stage development can require re-optimization.
Our solution
One chemistry from bench to clinic.
Glue4Life is designed so that the same underlying material chemistry can support development from early research toward clinically oriented manufacturing.
- Animal-free
- Hyaluronic acid-based
- Chemically defined
- Patent-protected chemistry
- Soft and elastic
- Injectable and printable
- No additional crosslinking required
- Designed for clinical translation
Traction
Scientific validation. Commercial momentum.
9
Peer-reviewed scientific publications
6
Products in the commercial portfolio
U.S.
Patent granted, further applications pending
EU · US · AU
Research users across Europe, the United States and Australia
4+
International awards and recognitions in 2025–2026
Selected recognition: NORDEEP Best Pitch · Nordic Life Science Days First Prize · Arctic15 · sTARTUp Day
View News & EventsCompetitive advantage
Built to be difficult to replace.
- Proprietary, patent-protected chemistry
- Chemically defined material platform
- Animal-free composition
- No additional crosslinking step
- Multiple tissue-specific formulations
- Same underlying chemistry across development stages
IP & clinical translation
Protected technology with clinical translation in mind.
- Glue4Life originates from research at Tampere University.
- The technology is based on patented intellectual property.
- A U.S. patent has been granted.
- Additional patent applications are pending in other key markets.
- Material design decisions have been made with future clinical translation and scalable manufacturing in mind.
Current Glue4Life products are for research use only and are not approved for clinical use.
Explore our technologyBusiness model
A platform designed to grow with our customers.
The business model is designed to support customers as their programs progress from early research toward clinical development. LifeGlue serves customers from academic and industrial R&D through biotech and medtech development toward later-stage manufacturing.
Stage 1 · Today
Research-use product sales
Commercial Glue4Life products for academic and industrial R&D.
Stage 2 · Next
Translational partnerships
Material optimization and collaboration as customer programs advance.
Stage 3 · Future
Clinical and GMP-oriented supply
Scalable material manufacturing for later-stage applications.
Roadmap
Scientific development
Achieved
Commercial research products
Achieved
International adoption
Achieved
Translational partnerships
Future goal
GMP manufacturing
Future goal
Future clinical applications
Future goal
Team
Built by scientists, operators and commercialization experts.
LifeGlue combines expertise in:
- Biomaterials and stem cell biology
- Biofabrication
- Manufacturing and quality
- Commercialization
- Intellectual property
- Customer applications
Laura Kuittinen
CEO and Co-Founder
Paula Puistola, DSc
COO and Co-Founder
Anni Mörö, PhD
CTO and Co-Founder
Interested in building the future of clinical biofabrication with us?
We welcome conversations with investors and strategic partners who share our ambition to bring advanced biofabrication technologies toward clinical use.